Aotearoa Covid Action (ACA) is calling on Pharmac to
reconsider its proposal
to award principal supply of Covid-19 vaccines exclusively
to Pfizer’s Comirnaty, citing concerns over limited access
and equity. The group has urged its members and others to
support Pharmac maintaining and widening vaccine access to
all who want them before the public consultation closes
today at 5:00 PM.
Pharmac’s current proposal would
fund only the Comirnaty vaccine, with alternative brands
available solely through its Exceptional Circumstances
framework. ACA believes this creates an exclusionary barrier
that may prevent some people from getting vaccinated or
boosted at all.
“If the goal is for as many Kiwis as
possible to be vaccinated and boosted, they must feel
engaged and empowered. Having a few options does this.
Comirnaty is an mRNA vaccine. It is contraindicated for
some, and some simply prefer a different, protein-based
vaccine such as Novavax. Pharmac should accommodate these
needs and preferences instead of promoting a
one-size-fits-all model,” says Julia Schiller, a
spokesperson for ACA.
In its own submission on the
proposal, ACA also suggests Pharmac widen the pool of New
Zealanders eligible for Covid vaccinations and boosters,
noting for example that regular boosters are unavailable to
the nearly 2 million Kiwis under the age of 30 and that
children under five cannot ordinarily receive any
vaccination at all.
Advertisement – scroll to continue reading
“Pharmac itself has
acknowledged that protection wanes significantly over time,
so it’s odd that they are not looking to widen eligibility
for boosters. Many of our under-30s would have last had a
booster years ago,” said Schiller.
The
organisation points out that recent
New Zealand research identified an “urgent need to
revise New Zealand’s eligibility criteria [and] make
vaccines available and accessible to younger age
groups”.
“The more we learn, the more we see that
Covid infections present a potential risk to all the
body’s organs and systems. Data suggests Long Covid is a
real consequence of at least 10% of infections. We simply
must do more to protect our tamariki and rangitahi and their
teachers, both for their own health and to reduce spread of
infections from schools to families to the greater
community. We need a diversified and accessible vaccination
strategy,” said Schiller.
Widening vaccine
availability aligns with the third demand of ACA’s ongoing
petition campaign, which advocates for more accessible
vaccinations and boosters, among other measures to slow the
transmission of airborne diseases.
“Winter has
arrived and with it, a jump in cases of influenza and Covid,
in particular the new variant NB.1.8.1,” Schiller added.
The World Health Organisation has designated NB.1.8.1 a
variant under monitoring. As of 29 May, it accounted for
21.6% of Aotearoa’s current Covid cases, according to
ESR’s wastewater monitoring.
“Pharmac must ensure
that a choice of vaccines is not only available but also
easily accessible to all, regardless of location or
circumstance. Pharmac approved five different formulations
of the flu vaccine this year so it seems reasonable to ask
they offer a choice of at least two different Covid
vaccines.”
Aotearoa Covid Action encourages
individuals and organizations to email their feedback on the
proposal to vaccines@pharmac.govt.nz
For
more information on Aotearoa Covid Action’s stance and to
support their petition, visit
Aotearoa Covid Action’s Website and
Clean Air in Schools
Petition.
© Scoop Media


















Discussion about this post